More Effective Suppression of Hemostatic System Activation in Patients Undergoing Cardiac Surgery by Heparin Dosing Based on Heparin Blood Concentrations rather than ACT

Summary This study was designed to determine whether the maintenance of higher than usual patient-specific heparin concentrations during cardiopulmonary bypass (CPB) was associated with more effective suppression of hemostasis system activation. Thirty-one patients scheduled for repeat cardiac sugery or combined procedures (i.e., coronary revascularization + valve repair/replacement) were consented and enrolled in this study. All patients received porcine heparin and protamine and were randomly assigned to monitoring of anticoagulation by either celite ACT alone (Control, n = 16) or by kaolin ACT combined with on-site measurements of whole blood heparin concentration (Intervention, n = 15). Blood specimens collected before administration of heparin, before weaning from CPB and after administration of protamine were analyzed with a battery of coagulation assays. Patients in the intervention cohort received appreciably greater heparin doses than control patients, resulting in higher anti-Xa heparin levels at the end of CPB. Fibrinopeptide A and D-dimer levels were higher in the control group before discontinuation of CPB. Percent decrease during CPB were greater in the control group for factors V and VIII, fibrinogen and antithrombin III. Percent decrease in complement 3 was greater in the control group after protamine and bleeding times measured in the Intensive Care Unit were significantly more prolonged in this group. Maintenance of higher patient-specific heparin concentrations during CPB more effectively suppresses excessive hemostatic system activation than do standard heparin doses chosen based on measurement of ACT. These findings may explain, at least in part, the significant reduction in perioperative blood loss and blood product use when higher heparin concentrations are maintained.

[1]  S. Stenbjerg,et al.  Heparin levels and activated clotting time (ACT) during open heart surgery. , 2009, Scandinavian journal of haematology.

[2]  T. Barrowcliffe,et al.  The influence of tissue source, salt and molecular weight and heparin activity. , 2009, Scandinavian journal of haematology. Supplementum.

[3]  C. Hogue,et al.  Factors Associated with Excessive Postoperative Blood Loss and Hemostatic Transfusion Requirements: A Multivariate Analysis in Cardiac Surgical Patients , 1996, Anesthesia and analgesia.

[4]  M. Jochum,et al.  Influence of High-dose Aprotinin on Anticoagulation, Heparin Requirement, and Celite- and Kaolin-Activated Clotting Time in Heparin-pretreated Patients Undergoing Open-Heart Surgery: A Double-blind, Placebo-controlled Study , 1995, Anesthesiology.

[5]  D. Jobes,et al.  Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. , 1995, The Journal of thoracic and cardiovascular surgery.

[6]  E. Spitznagel,et al.  Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. , 1994, The Journal of thoracic and cardiovascular surgery.

[7]  C. Osmer,et al.  Influence of different anticoagulation regimens on platelet function during cardiac surgery. , 1994, British journal of anaesthesia.

[8]  K. Hashimoto,et al.  Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. , 1994, The Annals of thoracic surgery.

[9]  L. Goodnough,et al.  The effect of an intraoperative treatment algorithm on physicians' transfusion practice in cardiac surgery , 1994, Transfusion.

[10]  C. Greenberg,et al.  Characterization of Prothrombin Activation during Cardiac Surgery by Hemostatic Molecular Markers , 1994, Anesthesiology.

[11]  E. Hoover,et al.  Neutrophil Lactoferrin Release During Open Heart Surgery Is Unrelated to Complement Activation , 1994, ASAIO journal.

[12]  I. Kovács,et al.  Inhibition of platelet function by heparin. An etiologic factor in postbypass hemorrhage. , 1993, The Journal of thoracic and cardiovascular surgery.

[13]  U. Abildgaard,et al.  Heparin/low molecular weight heparin and tissue factor pathway inhibitor. , 1993, Haemostasis.

[14]  S. Khuri,et al.  Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. , 1992, The Journal of thoracic and cardiovascular surgery.

[15]  G. Gravlee,et al.  Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. , 1992, Anesthesiology.

[16]  A. Lindahl,et al.  The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. , 1991, Thrombosis research.

[17]  M. Spannagl,et al.  The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. , 1991, The Journal of thoracic and cardiovascular surgery.

[18]  R. Hillman,et al.  Platelet activation and aggregation during cardiopulmonary bypass. , 1991, Anesthesiology.

[19]  Carolyn H. Fotouhi,et al.  Comparison study of the Hepcon System Four and the Hemostasis Management System , 1991, Perfusion.

[20]  R. Conroy,et al.  Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. , 1991, The Journal of clinical investigation.

[21]  J. Jespersen,et al.  Enhanced Effective Fibrinolysis following the Neutralization of Heparin in Open Heart Surgery Increases the Risk of Post-Surgical Bleeding , 1990, Thrombosis and Haemostasis.

[22]  G. Gravlee,et al.  Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. , 1990, The Journal of thoracic and cardiovascular surgery.

[23]  A. Keats,et al.  Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding. , 1990, The Annals of thoracic surgery.

[24]  J. Caprini,et al.  Decreased Platelet Number and Function and Increased Fibrinolysis Contribute to Postoperative Bleeding in Cardiopulmonary Bypass Patients , 1988, Thrombosis and Haemostasis.

[25]  J. Hirsh,et al.  Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. , 1986, Thrombosis research.

[26]  F. Ofosu,et al.  Heparin Cofactor II and Other Endogenous Factors in the Mediation of the Antithrombotic and Anticoagulant Effects of Heparin and Dermatan Sulfate , 1985, Seminars in thrombosis and hemostasis.

[27]  P. Diemunsch,et al.  Heparin monitoring during cardiopulmonary bypass. , 1984, Annals of clinical and laboratory science.

[28]  G. Gauvin,et al.  Heparin monitoring and neutralization during cardiopulmonary bypass using a rapid plasma separator and a fluorometric assay. , 1984, The Annals of thoracic surgery.

[29]  B. Bull,et al.  Platelet Involvement in the Activated Coagulation Time of Heparinized Blood , 1984, Anesthesia and analgesia.

[30]  S. Thomas,et al.  Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment. , 1983, The Journal of thoracic and cardiovascular surgery.

[31]  B. Bouma,et al.  The contact activation mechanism in human plasma: activation induced by dextran sulfate. , 1982, Blood.

[32]  A. Schwartz,et al.  Monitoring heparin anticoagulation and its neutralization. , 1981, The Annals of thoracic surgery.

[33]  K. Fujikawa,et al.  Surface activation of blood coagulation, fibrinolysis and kinin formation , 1980, Nature.

[34]  U. Lindahl,et al.  Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. , 1980, Thrombosis research.

[35]  C. Kisker,et al.  Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. , 1978, The Annals of thoracic surgery.

[36]  J. Verska Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis. , 1977, The Annals of thoracic surgery.

[37]  R. Pifarré,et al.  Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery. , 1977, The Journal of thoracic and cardiovascular surgery.

[38]  D. Doty,et al.  ANTICOAGULATION IN CARDIOPULMONARY BYPASS , 1977, Pediatric Research.

[39]  J. W. Bland,et al.  Successful Use of a Reduced Dose of Protamine After Cardiopulmonary Bypass , 1976, Anesthesia and analgesia.

[40]  B. Bull,et al.  Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. , 1975, The Journal of thoracic and cardiovascular surgery.

[41]  C. Mielke,et al.  A simple method of heparin management during prolonged extracorporeal circulation. , 1974, The Annals of thoracic surgery.

[42]  E. Spitznagel,et al.  Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. , 1994, The Journal of thoracic and cardiovascular surgery.

[43]  H. Philippou,et al.  Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. , 1993, Blood.

[44]  W. van Oeveren,et al.  Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. , 1993, The Journal of thoracic and cardiovascular surgery.

[45]  G. Savidge,et al.  Significance of the whole blood activated clotting time in cardiopulmonary bypass. , 1986, The Journal of cardiovascular surgery.

[46]  H. Stormorken,et al.  The value of activated coagulation time in monitoring heparin therapy during extracorporeal circulation. , 1984, Scandinavian journal of thoracic and cardiovascular surgery.

[47]  F. Spencer,et al.  Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. , 1981, Annals of surgery.

[48]  R. Rosenberg,et al.  Effect of heparin and heparin fractions on platelet aggregation. , 1980, The Journal of clinical investigation.

[49]  E. Cohen Activated clotting times and cardiopulmonary bypass I : The effect of hemodilution and hypothermia upon activated clotting time , 1980 .

[50]  B. Akl,et al.  Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass. , 1980, The Journal of thoracic and cardiovascular surgery.